

Code	Company Name	Country	Market	Market Cap (USD)	Revenue (USD)	Net Income (USD)	P/E Ratio	Dividend Yield	ROIC	Debt/Equity	EPS	EPS Growth
1011	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1012	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1013	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1014	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1015	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1016	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1017	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1018	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1019	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1020	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1021	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1022	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1023	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1024	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1025	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1026	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1027	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1028	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1029	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%
1030	Alkermes Corp	USA	Pharmaceuticals	12.5B	5.5B	1.1B	18.0	1.2%	18.0%	1.5	1.50	15%